Erin M. Corcoran

90 Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin’s Lymphoma

T. Waldmann, S. Pittaluga, M. Brechbiel, 2020 .

90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma.

T. Waldmann, S. Pittaluga, M. Brechbiel, 2020, Cancer biotherapy & radiopharmaceuticals.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

T. Waldmann, E. Jaffe, S. Pittaluga, 2015, Proceedings of the National Academy of Sciences.